Comparison of oral etoposide and standard intravenous multidrug chemotherapy for small-cell lung cancer: a stopped multicentre randomised trial
The LancetPublished 1 August 1996
D.J. Girling
Citations224
SJR quartileQ1
SJR score12.11
SNIP22.72
Generate an AI Snapshot to get a quick, structured summary of this paper.
Study Snapshot
ObjectiveStudy objective
MethodsResearch methodology
PopulationPopulation studied
Sample sizeSample sizes
OutcomesStudy outcomes here
ResultsStudy results comes here
LimitationsResearch study limitations comes here
A concise AI-generated summary of the paper will appear here once you click Generate AI Snapshot.
TL;DR
Oral etoposide alone is inferior to standard intravenous multidrug chemotherapy in the palliative treatment of patients with SCLC and poor performance status and should no longer be used in the treatment of such patients.
Abstract
Oral etoposide 50 mg twice daily for 10 days every 3 weeks for four cycles is inferior to standard intravenous multidrug chemotherapy in the palliative treatment of patients with SCLC and poor performance status. Oral etoposide alone should no longer be used in the treatment of such patients.
Keywords
MedicineBiochemistry, Genetics and Molecular Biology
Journal of Clinical OncologyA randomized trial to evaluate the effect of schedule on the activity of etoposide in small-cell lung cancer.
464 Citations1989M L Slevin, Peter Clark +7 more
This study has clearly demonstrated the importance of etoposide scheduling in humans, and the superiority of five daily infusions over a 24-hour continuous infusion.
British Journal of CancerAn overview of prognostic factors in small cell lung cancer
205 Citations1990NSB Rawson, J Peto
It is recommended that performance status, disease stage, AlkP, Na, AST and LDH should be measured in all future SCLC studies to assist comparisons between studies and possibly the selection of patients for different treatment strategies.
Cancer and its Management
146 Citations2009Jeffrey Tobias, Daniel Hochhauser
Journal of Clinical OncologyBioavailability of low-dose oral etoposide.
145 Citations1993Kenneth R. Hande, Mary G. Krozely +3 more
Bioavailability of a 100-mg oral etoposide dose is greater than suggested in the package insert from Bristol Laboratories (Evansville, IN), but Comparable oral etOPoside doses are not uniformly twice that of an IV dose, as suggested by the package inserts, but will depend on the final oral dose administered.
DigitalGeorgetown (Georgetown University Library)Introducing new treatments for cancer : practical, ethical and legal problems
132 Citations1992C J Williams
Partial table of contents: Ethics and consent, legal Aspects of Clinical Trials in the United Kingdom, and Good Clinical Research Practice.
Journal of Clinical OncologySchedule dependency of 21-day oral versus 3-day intravenous etoposide in combination with intravenous cisplatin in extensive-stage small-cell lung cancer: a randomized phase III study of the Cancer and Leukemia Group B.
106 Citations1995Antonius A. Miller, James E. Herndon +5 more
The two schedules of etoposide given as a conventional 3-day intravenous (IV) regimen versus a prolonged 21-day oral regimen for extensive-stage small-cell lung cancer (SCLC) did not result in differences in treatment outcome with respect to tumor response and survival.
British Journal of CancerRadiotherapy alone or with chemotherapy in the treatment of small-cell carcinoma of the lung.
76 Citations1979Medical Research Council Lung Cancer Working Party
It is concluded that radiotherapy plus chemotherapy was superior to radiotherapy alone, although chemotherapy did not protect patients from recurrence of primary growth.
European Journal of Cancer and Clinical OncologyVariable bioavailability following repeated oral doses of etoposide
64 Citations1985V.J. Harvey, M L Slevin +4 more
The data indicate that etoposide bioavailability is not constant and oral therapy may lead to unsuspected underdosing or unexpected toxicity in schedules extending over several days, and monitoring blood concentrations for a single day following oral therapy should be avoided.
CancerCurrent status of therapy for small cell carcinoma of the lung
61 Citations1984Daniel C. Ihde
Current areas of active clinical investigation in SCCL are reviewed and some information developed in the cell biology laboratory that may have eventual application in the clinic are reviewed.
British Journal of CancerRandomised trial of four-drug vs less intensive two-drug chemotherapy in the palliative treatment of patients with small-cell lung cancer (SCLC) and poor prognosis
55 Citations1996NM Bleehen, DJ Girling +5 more
The levels of palliation were high and similar in the two groups, although the ECMV regimen was on balance superior in palliating physical symptoms and reducing psychological distress, and the EV regimen is a useful palliative regimen for patients with SCLC and poor prognosis.
PubMedThe activity of 10-, 14-, and 21-day schedules of single-agent etoposide in previously untreated patients with extensive small cell lung cancer.
50 Citations1992Peter Clark, B. Cottier
These studies demonstrate that prolonged administration of low-dose oral etoposide is very active in small cell lung cancer, and that a twice-daily regimen is preferable in view of the greater rapidity of response and possibly higher response rate.
Lung CancerTreatment-related deaths in small cell lung cancer trials: can patients at risk be identified?
38 Citations1994Richard Stephens, D.J. Girling +1 more
This model identified a high risk group of patients with an excess death rate of more than 15% in the second week after starting chemotherapy, and Radford et als' suggestion that high risk patients be given half doses of drugs at the first cycle should be tested in a randomised clinical trial.